{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:45:26Z","timestamp":1771976726548,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s10067-025-07533-6","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:08:23Z","timestamp":1749773303000},"page":"2601-2610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of rituximab versus cyclophosphamide in connective tissue disease\u2011related interstitial lung disease: a\u00a0systematic review and meta-analysis"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1490-8602","authenticated-orcid":false,"given":"Yan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoxiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junlai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoxing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4326-212X","authenticated-orcid":false,"given":"Shuiming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"7","key":"7533_CR1","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1177\/0885066613516579","volume":"30","author":"JJ Solomon","year":"2015","unstructured":"Solomon JJ, Fischer A (2015) Connective tissue disease-associated interstitial lung disease: a focused review. J Intensive Care Med 30(7):392\u2013400","journal-title":"J Intensive Care Med"},{"issue":"2","key":"7533_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/resp.12588","volume":"21","author":"V Cottin","year":"2016","unstructured":"Cottin V (2016) Idiopathic interstitial pneumonias with connective tissue diseases features: a review. Respirology 21(2):245\u2013258","journal-title":"Respirology"},{"issue":"3","key":"7533_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1055\/s-0044-1786155","volume":"45","author":"E Mulcaire-Jones","year":"2024","unstructured":"Mulcaire-Jones E, Pugashetti JV, Oldham JM et al (2024) Novel Therapeutic approaches in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med 45(3):435\u2013448","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"7533_CR4","doi-asserted-by":"publisher","first-page":"e20230132","DOI":"10.36416\/1806-3756\/e20230132","volume":"50","author":"KM Storrer","year":"2024","unstructured":"Storrer KM, M\u00fcller CS, Pessoa MCA et al (2024) Connective tissue disease-associated interstitial lung disease. J Bras Pneumol 50(1):e20230132","journal-title":"J Bras Pneumol"},{"issue":"4","key":"7533_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/ar3097","volume":"12","author":"FV Castelino","year":"2010","unstructured":"Castelino FV, Varga J (2010) Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther 12(4):213","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"7533_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/BOR.0000000000000795","volume":"33","author":"D Roofeh","year":"2021","unstructured":"Roofeh D, Lescoat A, Khanna D (2021) Treatment for systemic sclerosis-associated interstitial lung disease. Curr Opin Rheumatol 33(3):240\u2013248","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"7533_CR7","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","volume":"57","author":"G Sircar","year":"2018","unstructured":"Sircar G, Goswami RP, Sircar D et al (2018) Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford) 57(12):2106\u20132113","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"7533_CR8","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327\u20131339","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7533_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13075-023-03090-y","volume":"25","author":"JP Higuero Sevilla","year":"2023","unstructured":"Higuero Sevilla JP, Memon A, Hinchcliff M (2023) Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease. Arthritis Res Ther 25(1):118","journal-title":"Arthritis Res Ther"},{"key":"7533_CR10","doi-asserted-by":"crossref","unstructured":"Vacchi C, Manfredi A, Cassone G, et al. (2021) Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease. Drugs Context\u00a010:2020-8-7","DOI":"10.7573\/dic.2020-8-7"},{"issue":"1","key":"7533_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1513\/AnnalsATS.202301-053OC","volume":"21","author":"H Barnes","year":"2024","unstructured":"Barnes H, Ghazipura M, Herman D et al (2024) Cyclophosphamide in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis. Ann Am Thorac Soc 21(1):122\u2013135","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"7533_CR12","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.3390\/jcm9082560","volume":"9","author":"GL Erre","year":"2020","unstructured":"Erre GL, Sebastiani M, Fenu MA et al (2020) Efficacy, safety, and tolerability of treatments for systemic sclerosis-related interstitial lung disease: a systematic review and network meta-analysis. J Clin Med 9(8):2560","journal-title":"J Clin Med"},{"key":"7533_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J et al (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"7533_CR14","first-page":"142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ et al (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 10(10):142","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"7533_CR15","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","volume":"3","author":"S Ebata","year":"2021","unstructured":"Ebata S, Yoshizaki A, Oba K et al (2021) Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 3(7):e489\u2013e497","journal-title":"Lancet Rheumatol"},{"issue":"10","key":"7533_CR16","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1007\/s10067-021-05785-6","volume":"40","author":"DD Yilmaz","year":"2021","unstructured":"Yilmaz DD, Borekci S, Musellim B (2021) Comparison of the effectiveness of cyclophosphamide and rituximab treatment in patients with systemic sclerosis-related interstitial lung diseases: a retrospective, observational cohort study. Clin Rheumatol 40(10):4071\u20139","journal-title":"Clin Rheumatol"},{"key":"7533_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/annrheumdis-2019-eular.6816","volume":"78","author":"O Koneva","year":"2019","unstructured":"Koneva O, Ananyeva LP, Garzanova L et al (2019) Rituximab and cyclophosphamide comparison for efficacy and safety in the patients with systemic sclerosis associated with interstitial lung disease. Ann Rheum Dis 78:169","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"7533_CR18","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.3899\/jrheum.190505","volume":"47","author":"V Langlois","year":"2020","unstructured":"Langlois V, Gillibert A, Uzunhan Y et al (2020) Rituximab and cyclophosphamide in antisynthetase syndrome-related interstitial lung disease: an observational retrospective study. J Rheumatol 47(11):1678\u20131686","journal-title":"J Rheumatol"},{"issue":"1","key":"7533_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher TM, Tudor VA, Saunders P et al (2023) Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 11(1):45\u201354","journal-title":"Lancet Respir Med"},{"issue":"Suppl 1","key":"7533_CR20","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1136\/annrheumdis-2020-eular.4267","volume":"79","author":"O Koneva","year":"2020","unstructured":"Koneva O, Ananieva L, Garzanova L et al (2020) AB0583 comparison of the RITUXIMAB (RTM) in monotherapy Regimen and Cyclophosphomide (CYP) efficacy and Safety in Systemic Sclerosis (SSC) with Interstitial Lung Disease (ILD). Ann Rheum Dis 79(Suppl 1):1588\u20131589","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 5","key":"7533_CR21","first-page":"v1","volume":"63","author":"B Bradley","year":"2008","unstructured":"Bradley B, Branley HM, Egan JJ et al (2008) Interstitial lung disease guideline: the British thoracic society in collaboration with the thoracic society of Australia and New Zealand and the Irish thoracic society. Thorax 63(Suppl 5):v1-58","journal-title":"Thorax"},{"key":"7533_CR22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.41959","volume":"74","author":"T Maher","year":"2022","unstructured":"Maher T, Tudor V, Saunders P et al (2022) Rituximab versus cyclophosphamide for the treatment of connective tissue disease associated interstitial lung disease (RECITAL): a subgroup analysis of a multi-centre randomised controlled trial. Arthritis Rheumatol 74:5\u20137","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"7533_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/rheumatology\/key151","volume":"58","author":"D Khanna","year":"2019","unstructured":"Khanna D, Tashkin DP, Denton CP et al (2019) Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford) 58(4):567\u2013579","journal-title":"Rheumatology (Oxford)"},{"issue":"25","key":"7533_CR24","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655\u20132666","journal-title":"N Engl J Med"},{"issue":"8","key":"7533_CR25","first-page":"e68279","volume":"16","author":"A Parikh","year":"2024","unstructured":"Parikh A, Francis AJ, Sreenivasan C et al (2024) Efficacy of rituximab versus cyclophosphamide and mycophenolate for the treatment of interstitial lung disease in systemic sclerosis: a systematic review. Cureus 16(8):e68279","journal-title":"Cureus"},{"key":"7533_CR26","doi-asserted-by":"publisher","first-page":"152164","DOI":"10.1016\/j.semarthrit.2023.152164","volume":"59","author":"V Moreno-Torres","year":"2023","unstructured":"Moreno-Torres V, Mart\u00edn-Iglesias D, Vivero F et al (2023) Intravenous cyclophosphamide improves functional outcomes in interstitial lung disease related to idiopathic inflammatory myopathies. Semin Arthritis Rheum 59:152164","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"7533_CR27","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1513\/AnnalsATS.201606-426FR","volume":"13","author":"ER Volkmann","year":"2016","unstructured":"Volkmann ER, Tashkin DP (2016) Treatment of systemic sclerosis-related interstitial lung disease: a review of existing and emerging therapies. Ann Am Thorac Soc 13(11):2045\u20132056","journal-title":"Ann Am Thorac Soc"},{"issue":"10","key":"7533_CR28","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.autrev.2011.04.013","volume":"10","author":"S Bosello","year":"2011","unstructured":"Bosello S, de Luca G, Tolusso B et al (2011) B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 10(10):624\u2013630","journal-title":"Autoimmun Rev"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07533-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07533-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07533-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:46:34Z","timestamp":1751874394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07533-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7533"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07533-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"25 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement for the use of human and animal subjects (may require consent to participate and consent to publish for human subjects)"}},{"value":"All authors have read and approved the final submitted manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}